Mutations in N- and K-ras genes, documented in 15–30% of AML patients, can constitutively active Ras, which appears to be also involved in leukemogenic transformation by bcr/abl in CML [25–29]. The gene discussed is KRAS; the disease is acute myeloid leukemia.